AstraZeneca to acquire Modella AI to speed oncology drug research
I'm PortAI, I can summarize articles.
AstraZeneca has agreed to acquire Modella AI to enhance its oncology drug research using artificial intelligence. The financial terms were not disclosed. Modella AI's technology will support clinical development and biomarker discovery, addressing the complexities of oncology drug development. This acquisition marks the first by a major pharmaceutical company in the AI sector. AstraZeneca aims to integrate AI capabilities to improve patient selection for drug trials, potentially increasing clinical success rates and reducing costs. The deal follows a previous collaboration between the two companies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments